Publication at Third Faculty of Medicine |
2015
Abstract
DPP-4 inhibitors, i.e. gliptins, are a heterogeneous group of relatively small molecules - with low molecular weight. All gliptins in use today, nonetheless, are highly effective drugs as have been shown in a number of clinical studies, including recently published meta-analyses.
This explains the solid position of these drugs in the therapy of type 2 diabetes.